Last updated: February 15, 2026
Product Overview and Indication
NDC 00173-0717 corresponds to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor approved by the FDA for multiple indications. It primarily treats melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, Hodgkin lymphoma, and other solid tumors. Its mechanism involves blocking PD-1 receptors, thereby enhancing immune response against tumors.
Market Size and Competitive Landscape
-
Estimated Market Size (2023):
The global cancer immunotherapy market was valued at approximately $40 billion in 2022. Nivolumab accounts for a significant share, driven by its approvals across multiple indications.
-
US Market (2023):
Estimated at $8-10 billion in sales, with rising demand in lung, melanoma, and renal cancer segments. The expansion into new indications, such as gastric and esophageal cancers, supports growth projections.
-
Key Competitors:
Pembrolizumab (Keytruda), Atezolizumab (Tecentriq), Durvalumab (Imfinzi). Pembrolizumab is its closest competitor, with similar indications and a comparable sales footprint (> $15 billion in 2022).
-
Pricing Strategies & Reimbursement Landscape:
- Average Wholesale Price (AWP):
Estimated at $5,000 to $7,000 per dose (per 40 mg or 20 mg vials).
- Reimbursement:
Managed by Medicare, Medicaid, private insurers. High-cost drugs like Nivolumab face increasing push for value-based arrangements.
- Pricing Trends:
Price increases have slowed due to market competition and payer negotiations but remain high due to complex administration and manufacturing costs.
Pricing Projections (2024-2028)
| Year |
Estimated Average Price per Dose |
Market Growth Rate |
Key Factors Influencing Price |
| 2024 |
$5,500 |
8% |
Competitive landscape, inflation in manufacturing, evolving reimbursement policies |
| 2025 |
$5,900 |
7% |
Introduction of biosimilars in some markets, patent expirations not imminent |
| 2026 |
$6,200 |
6% |
Increased deployment in earlier lines of therapy, potential biosimilar entry delayed |
| 2027 |
$6,600 |
5% |
Market saturation, price negotiation pressures |
| 2028 |
$7,000 |
4% |
Launch of alternative therapies, price caps in some regions |
Trends Affecting Future Pricing:
-
Biosimilar Competition:
Biosimilars for nivolumab are in early development stages, with potential entry post-2030. Their arrival could pressure pricing downward.
-
Indication Expansion:
As approvals extend into earlier lines of treatment and new cancers, increased treatment volume may stabilize or slightly decrease per-unit price due to volume discounts.
-
Market Access & Reimbursement Dynamics:
Payers seek value-based pricing agreements. Outcomes-based contracts may influence net pricing, often reducing net revenue despite high sticker prices.
-
Global Market Variability:
Emerging markets are adopting nivolumab under lower price points, impacting overall revenue. Patent protection remains key in high-price regions until mid-2020s.
Regulatory and Policy Impact
-
Patent Life & Exclusivity:
Patents expire around 2028-2030. Patent expiry opens opportunity for biosimilars, exerting downward pressure.
-
Pricing Regulations:
Several governments (e.g., the UK, Germany, Canada) implement price caps or negotiation policies targeting high-cost drugs, influencing future pricing strategies.
Summary
Nivolumab (NDC 00173-0717) maintains a high-value position in oncology but faces eventual price compression driven by biosimilar entry, market saturation, and policy regulation. Expected average price per dose increases modestly from $5,500 in 2024 to around $7,000 by 2028. Market growth is expected to slow gradually, with volume expansion partially offsetting price pressures.
Key Takeaways
- Nivolumab remains a leading immunotherapy with substantial sales in the US and global markets.
- Price projections show steady increases through 2028, constrained by biosimilar competition and policy measures.
- Market expansion into new indications and earlier lines sustains revenue growth despite pricing pressures.
- Biosimilar development and patent expirations will be catalysts for future price reductions.
- Reimbursement models are shifting towards value-based systems, influencing net revenues over nominal list prices.
FAQs
-
When might biosimilars for nivolumab become available?
Biosimilars are under development, with potential approval around 2030, depending on regulatory timelines.
-
How does nivolumab compare price-wise to its competitors?
Its average wholesale price is comparable to pembrolizumab, within the $5,000-$7,000 per dose range; actual costs vary with volume and negotiated discounts.
-
What new indications could impact the market?
Nivolumab is being evaluated for head and neck cancers, gastric cancers, and in combination therapies, which could broaden its market.
-
How do policy changes affect nivolumab prices?
Price caps, negotiation policies, and outcomes-based agreements could cap or reduce net prices, especially in the EU and Canada.
-
What is the outlook beyond 2028?
Patent expiration and biosimilar competition are poised to significantly lower prices, shifting market dynamics towards more affordable therapies.
Sources
[1] IQVIA, 2023. Global Oncology Market Report.
[2] FDA, 2022. Nivolumab (Opdivo) Label.
[3] EvaluatePharma, 2022. Oncology Drug Market Analysis.
[4] CMS, 2023. Reimbursement Policies for High-Cost Oncology Drugs.
[5] Biosimilar Development Reports, 2023.
